JSLL achieves strong Q1 FY26 with 74% YoY revenue growth
The strong financial performance, expansion plans, and new product launches are likely to have a significant positive impact on the company's future growth and market position.
The announcement highlights significant revenue and profit growth, expansion of services, and strategic initiatives, indicating a positive outlook for the company.
* Jeena Sikho Lifecare (JSLL) reported strong Q1 FY26 results with revenue from operations at ₹174 crore, a 74% year-on-year growth compared to ₹100 crore in Q1 FY25. * Profit after tax (PAT) increased by 218% year-on-year to ₹51 crore, with an EPS of ₹4.13. * EBITDA stood at ₹79 crore with a profitability margin of around 45%. * The company saw a 70% year-on-year increase in OPD and over 45% year-on-year growth in IPD patient volumes. * Operational bed capacity increased to 2,570 beds with the addition of 390 beds. * JSLL successfully migrated to the main board of NSE and BSE on August 11, 2025. * The company is launching an OTC product called PET Liver Spleen Shuddi Kit for ₹960 to promote healthy living and address weak digestion. * JSLL has tied up with two new labs for cancer tests using HRC and blood-based biopsy. * The company is also working on AI chatbot-based apps for BP, sugar, depression, and anxiety management. * Management aims for ₹700 crore turnover this year from hospital and clinic business and ₹500 crore in 1-2 years from the medical business. * The company is planning to maintain a profit margin of 20% to 25%. * JSLL is providing free treatment to 10% of patients in every hospital to help the poor and reduce ad expenses. * The company has tied up with three medical colleges to build 7,000 to 10,000 beds in the next five years. * JSLL is opening clinics in Dubai and Abu Dhabi and has received a profit of around ₹10 lakh from its Nepal operations.
What to do with a filing like this
Jeena Sikho Lifecare Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jeena Sikho Lifecare Limited. Read the original for the full detail.